Experimental pulmonary embolism

Effects of the thrombus and attenuation of pulmonary artery injury by low-molecular-weight heparin

John E. Rectenwald, K. Barry Deatrick, Pasu Sukheepod, Erin M. Lynch, Andrea J. Moore, Daria Moaveni, Nicholas A. Deywer, Catherine E. Luke, Gilbert R. Upchurch, Thomas W. Wakefield, Steven L. Kunkel, Peter K. Henke

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Pulmonary embolism (PE) is a life-threatening condition that is associated with the long-term sequelae of chronic pulmonary hypertension. Prior experimental work has suggested that post-PE inflammation is accompanied by pulmonary artery intimal hyperplasia. This study evaluated the effect of the thrombus and tested the hypothesis that thrombolytic, antiplatelet, and anticoagulant agents would decrease pulmonary injury. Methods: Male Sprague-Dawley rats (n = 267) underwent laparotomy and temporary clip occlusion of the infrarenal inferior vena cava for the formation of endogenous thrombus or placement of an inert silicone "thrombus." Two days later, repeat laparotomy was performed, the clip removed, and the thrombus or silicone plug was embolized to the lungs. The endogenous thrombus group received normal saline, low-molecular-weight heparin (LMWH), tissue plasminogen activator (tPA), or a gIIB/IIIA antagonist (abciximab). Lung tissue was harvested at various times over 21 days and assayed for total collagen, monocyte chemoattractant protein-1 (MCP-1), interleukin-13 (IL-13), and transforming growth factor-β (TGF-β). Fixed sections were stained with trichrome for intimal hyperplasia determination and ED-1 monocytes and α-actin-positive staining. Results: The overall survival for rats undergoing PE was 90%, was not affected by treatment, and 84% of all PE localized to the right pulmonary artery. The PE significantly reduced Pao 2 in all groups. Compared with controls, the silicone emboli group had an increased level of IL-13 on day 1, an increased level of MCP-1 on day 4, and an increase in the levels of all inflammatory mediators on day 14 (P < .05). Accompanying these differences were greater pulmonary artery intimal hyperplasia at days 4 and 21 in the silicone group compared with controls (P < .05). LMWH treatment in the thrombus of PE rats significantly decreased IL-13 levels at all time points, whereas treatment with abciximab or tPA significantly increased IL-13 levels compared with controls. TGF-β levels were significantly increased by LMWH at day 4 and 14, and abciximab was associated with lower TGF-β at day 14. Only LMWH was associated with less pulmonary artery intimal hyperplasia at day 14 compared with controls and the other treatment groups. Conclusions: Persistent pulmonary artery distention by an inert material is sufficient to invoke significant inflammation and intimal hyperplasia independent of the thrombus itself. Compared with nontreated PE, LMWH is the only therapy associated with a significant reduction in late intimal hyperplasia and, with the exception of TGF-β, lower profibrotic growth-factor production.

Original languageEnglish (US)
Pages (from-to)800-808
Number of pages9
JournalJournal of Vascular Surgery
Volume43
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Tunica Intima
Low Molecular Weight Heparin
Lung Injury
Pulmonary Embolism
Pulmonary Artery
Thrombosis
Hyperplasia
Interleukin-13
Transforming Growth Factors
Silicones
Chemokine CCL2
Tissue Plasminogen Activator
Surgical Instruments
Laparotomy
Lung
Fibrinolytic Agents
Platelet Aggregation Inhibitors
Inferior Vena Cava
Embolism
Pulmonary Hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Experimental pulmonary embolism : Effects of the thrombus and attenuation of pulmonary artery injury by low-molecular-weight heparin. / Rectenwald, John E.; Deatrick, K. Barry; Sukheepod, Pasu; Lynch, Erin M.; Moore, Andrea J.; Moaveni, Daria; Deywer, Nicholas A.; Luke, Catherine E.; Upchurch, Gilbert R.; Wakefield, Thomas W.; Kunkel, Steven L.; Henke, Peter K.

In: Journal of Vascular Surgery, Vol. 43, No. 4, 04.2006, p. 800-808.

Research output: Contribution to journalArticle

Rectenwald, JE, Deatrick, KB, Sukheepod, P, Lynch, EM, Moore, AJ, Moaveni, D, Deywer, NA, Luke, CE, Upchurch, GR, Wakefield, TW, Kunkel, SL & Henke, PK 2006, 'Experimental pulmonary embolism: Effects of the thrombus and attenuation of pulmonary artery injury by low-molecular-weight heparin', Journal of Vascular Surgery, vol. 43, no. 4, pp. 800-808. https://doi.org/10.1016/j.jvs.2005.12.010
Rectenwald, John E. ; Deatrick, K. Barry ; Sukheepod, Pasu ; Lynch, Erin M. ; Moore, Andrea J. ; Moaveni, Daria ; Deywer, Nicholas A. ; Luke, Catherine E. ; Upchurch, Gilbert R. ; Wakefield, Thomas W. ; Kunkel, Steven L. ; Henke, Peter K. / Experimental pulmonary embolism : Effects of the thrombus and attenuation of pulmonary artery injury by low-molecular-weight heparin. In: Journal of Vascular Surgery. 2006 ; Vol. 43, No. 4. pp. 800-808.
@article{0eb0bf83a2dc433abbc387b5fa07f9b1,
title = "Experimental pulmonary embolism: Effects of the thrombus and attenuation of pulmonary artery injury by low-molecular-weight heparin",
abstract = "Background: Pulmonary embolism (PE) is a life-threatening condition that is associated with the long-term sequelae of chronic pulmonary hypertension. Prior experimental work has suggested that post-PE inflammation is accompanied by pulmonary artery intimal hyperplasia. This study evaluated the effect of the thrombus and tested the hypothesis that thrombolytic, antiplatelet, and anticoagulant agents would decrease pulmonary injury. Methods: Male Sprague-Dawley rats (n = 267) underwent laparotomy and temporary clip occlusion of the infrarenal inferior vena cava for the formation of endogenous thrombus or placement of an inert silicone {"}thrombus.{"} Two days later, repeat laparotomy was performed, the clip removed, and the thrombus or silicone plug was embolized to the lungs. The endogenous thrombus group received normal saline, low-molecular-weight heparin (LMWH), tissue plasminogen activator (tPA), or a gIIB/IIIA antagonist (abciximab). Lung tissue was harvested at various times over 21 days and assayed for total collagen, monocyte chemoattractant protein-1 (MCP-1), interleukin-13 (IL-13), and transforming growth factor-β (TGF-β). Fixed sections were stained with trichrome for intimal hyperplasia determination and ED-1 monocytes and α-actin-positive staining. Results: The overall survival for rats undergoing PE was 90{\%}, was not affected by treatment, and 84{\%} of all PE localized to the right pulmonary artery. The PE significantly reduced Pao 2 in all groups. Compared with controls, the silicone emboli group had an increased level of IL-13 on day 1, an increased level of MCP-1 on day 4, and an increase in the levels of all inflammatory mediators on day 14 (P < .05). Accompanying these differences were greater pulmonary artery intimal hyperplasia at days 4 and 21 in the silicone group compared with controls (P < .05). LMWH treatment in the thrombus of PE rats significantly decreased IL-13 levels at all time points, whereas treatment with abciximab or tPA significantly increased IL-13 levels compared with controls. TGF-β levels were significantly increased by LMWH at day 4 and 14, and abciximab was associated with lower TGF-β at day 14. Only LMWH was associated with less pulmonary artery intimal hyperplasia at day 14 compared with controls and the other treatment groups. Conclusions: Persistent pulmonary artery distention by an inert material is sufficient to invoke significant inflammation and intimal hyperplasia independent of the thrombus itself. Compared with nontreated PE, LMWH is the only therapy associated with a significant reduction in late intimal hyperplasia and, with the exception of TGF-β, lower profibrotic growth-factor production.",
author = "Rectenwald, {John E.} and Deatrick, {K. Barry} and Pasu Sukheepod and Lynch, {Erin M.} and Moore, {Andrea J.} and Daria Moaveni and Deywer, {Nicholas A.} and Luke, {Catherine E.} and Upchurch, {Gilbert R.} and Wakefield, {Thomas W.} and Kunkel, {Steven L.} and Henke, {Peter K.}",
year = "2006",
month = "4",
doi = "10.1016/j.jvs.2005.12.010",
language = "English (US)",
volume = "43",
pages = "800--808",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Experimental pulmonary embolism

T2 - Effects of the thrombus and attenuation of pulmonary artery injury by low-molecular-weight heparin

AU - Rectenwald, John E.

AU - Deatrick, K. Barry

AU - Sukheepod, Pasu

AU - Lynch, Erin M.

AU - Moore, Andrea J.

AU - Moaveni, Daria

AU - Deywer, Nicholas A.

AU - Luke, Catherine E.

AU - Upchurch, Gilbert R.

AU - Wakefield, Thomas W.

AU - Kunkel, Steven L.

AU - Henke, Peter K.

PY - 2006/4

Y1 - 2006/4

N2 - Background: Pulmonary embolism (PE) is a life-threatening condition that is associated with the long-term sequelae of chronic pulmonary hypertension. Prior experimental work has suggested that post-PE inflammation is accompanied by pulmonary artery intimal hyperplasia. This study evaluated the effect of the thrombus and tested the hypothesis that thrombolytic, antiplatelet, and anticoagulant agents would decrease pulmonary injury. Methods: Male Sprague-Dawley rats (n = 267) underwent laparotomy and temporary clip occlusion of the infrarenal inferior vena cava for the formation of endogenous thrombus or placement of an inert silicone "thrombus." Two days later, repeat laparotomy was performed, the clip removed, and the thrombus or silicone plug was embolized to the lungs. The endogenous thrombus group received normal saline, low-molecular-weight heparin (LMWH), tissue plasminogen activator (tPA), or a gIIB/IIIA antagonist (abciximab). Lung tissue was harvested at various times over 21 days and assayed for total collagen, monocyte chemoattractant protein-1 (MCP-1), interleukin-13 (IL-13), and transforming growth factor-β (TGF-β). Fixed sections were stained with trichrome for intimal hyperplasia determination and ED-1 monocytes and α-actin-positive staining. Results: The overall survival for rats undergoing PE was 90%, was not affected by treatment, and 84% of all PE localized to the right pulmonary artery. The PE significantly reduced Pao 2 in all groups. Compared with controls, the silicone emboli group had an increased level of IL-13 on day 1, an increased level of MCP-1 on day 4, and an increase in the levels of all inflammatory mediators on day 14 (P < .05). Accompanying these differences were greater pulmonary artery intimal hyperplasia at days 4 and 21 in the silicone group compared with controls (P < .05). LMWH treatment in the thrombus of PE rats significantly decreased IL-13 levels at all time points, whereas treatment with abciximab or tPA significantly increased IL-13 levels compared with controls. TGF-β levels were significantly increased by LMWH at day 4 and 14, and abciximab was associated with lower TGF-β at day 14. Only LMWH was associated with less pulmonary artery intimal hyperplasia at day 14 compared with controls and the other treatment groups. Conclusions: Persistent pulmonary artery distention by an inert material is sufficient to invoke significant inflammation and intimal hyperplasia independent of the thrombus itself. Compared with nontreated PE, LMWH is the only therapy associated with a significant reduction in late intimal hyperplasia and, with the exception of TGF-β, lower profibrotic growth-factor production.

AB - Background: Pulmonary embolism (PE) is a life-threatening condition that is associated with the long-term sequelae of chronic pulmonary hypertension. Prior experimental work has suggested that post-PE inflammation is accompanied by pulmonary artery intimal hyperplasia. This study evaluated the effect of the thrombus and tested the hypothesis that thrombolytic, antiplatelet, and anticoagulant agents would decrease pulmonary injury. Methods: Male Sprague-Dawley rats (n = 267) underwent laparotomy and temporary clip occlusion of the infrarenal inferior vena cava for the formation of endogenous thrombus or placement of an inert silicone "thrombus." Two days later, repeat laparotomy was performed, the clip removed, and the thrombus or silicone plug was embolized to the lungs. The endogenous thrombus group received normal saline, low-molecular-weight heparin (LMWH), tissue plasminogen activator (tPA), or a gIIB/IIIA antagonist (abciximab). Lung tissue was harvested at various times over 21 days and assayed for total collagen, monocyte chemoattractant protein-1 (MCP-1), interleukin-13 (IL-13), and transforming growth factor-β (TGF-β). Fixed sections were stained with trichrome for intimal hyperplasia determination and ED-1 monocytes and α-actin-positive staining. Results: The overall survival for rats undergoing PE was 90%, was not affected by treatment, and 84% of all PE localized to the right pulmonary artery. The PE significantly reduced Pao 2 in all groups. Compared with controls, the silicone emboli group had an increased level of IL-13 on day 1, an increased level of MCP-1 on day 4, and an increase in the levels of all inflammatory mediators on day 14 (P < .05). Accompanying these differences were greater pulmonary artery intimal hyperplasia at days 4 and 21 in the silicone group compared with controls (P < .05). LMWH treatment in the thrombus of PE rats significantly decreased IL-13 levels at all time points, whereas treatment with abciximab or tPA significantly increased IL-13 levels compared with controls. TGF-β levels were significantly increased by LMWH at day 4 and 14, and abciximab was associated with lower TGF-β at day 14. Only LMWH was associated with less pulmonary artery intimal hyperplasia at day 14 compared with controls and the other treatment groups. Conclusions: Persistent pulmonary artery distention by an inert material is sufficient to invoke significant inflammation and intimal hyperplasia independent of the thrombus itself. Compared with nontreated PE, LMWH is the only therapy associated with a significant reduction in late intimal hyperplasia and, with the exception of TGF-β, lower profibrotic growth-factor production.

UR - http://www.scopus.com/inward/record.url?scp=33645743243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645743243&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2005.12.010

DO - 10.1016/j.jvs.2005.12.010

M3 - Article

VL - 43

SP - 800

EP - 808

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 4

ER -